S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NASDAQ:ENTX

Entera Bio Stock Forecast, Price & News

$3.16
+0.01 (+0.32%)
(As of 12/7/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.13
$3.30
50-Day Range
$3.12
$4.89
52-Week Range
$1.01
$10.16
Volume
48,103 shs
Average Volume
3.23 million shs
Market Capitalization
$74.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.58
30 days | 90 days | 365 days | Advanced Chart
Receive ENTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.


Entera Bio logo

About Entera Bio

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.

Headlines

B. Riley Weighs in on Entera Bio Ltd.'s FY2021 Earnings (NASDAQ:ENTX)
November 15, 2021 |  americanbankingnews.com
Entera Bio Reports Third Quarter 2021 Financial Results
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTX
Fax
N/A
Employees
17
Year Founded
N/A

Sales & Book Value

Annual Sales
$370 thousand
Book Value
$1.10 per share

Profitability

Net Income
$-9.98 million
Net Margins
-3,086.76%
Pretax Margin
-3,063.96%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$74.89 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/17/2022

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

935th out of 1,394 stocks

Biological Products, Except Diagnostic Industry

138th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Entera Bio (NASDAQ:ENTX) Frequently Asked Questions

Is Entera Bio a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Entera Bio stock.
View analyst ratings for Entera Bio
or view top-rated stocks.

How has Entera Bio's stock been impacted by COVID-19?

Entera Bio's stock was trading at $2.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ENTX shares have increased by 13.7% and is now trading at $3.16.
View which stocks have been most impacted by COVID-19
.

When is Entera Bio's next earnings date?

Entera Bio is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Entera Bio
.

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) issued its quarterly earnings results on Thursday, November, 11th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. Entera Bio had a negative trailing twelve-month return on equity of 118.06% and a negative net margin of 3,086.76%.
View Entera Bio's earnings history
.

What price target have analysts set for ENTX?

3 brokers have issued 1-year target prices for Entera Bio's shares. Their forecasts range from $10.00 to $12.00. On average, they anticipate Entera Bio's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 248.1% from the stock's current price.
View analysts' price targets for Entera Bio
or view top-rated stocks among Wall Street analysts.

Who are Entera Bio's key executives?

Entera Bio's management team includes the following people:
  • Spiros Jamas, Chief Executive Officer & Director
  • Hillel Galitzer, Chief Operating Officer
  • Dana Yaacov-Garbeli, Chief Financial Officer
  • Phillip Schwartz, Director, EVP, President-Research & Development
  • Arthur C. Santora, Chief Medical Officer

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include (CGC), Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

When did Entera Bio IPO?

(ENTX) raised $11 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager.

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

Who are Entera Bio's major shareholders?

Entera Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Citadel Advisors LLC (0.00%), Millennium Management LLC (0.08%), Jane Street Group LLC (0.05%), Morgan Stanley (0.02%) and HAP Trading LLC (0.00%).

Which institutional investors are selling Entera Bio stock?

ENTX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Millennium Management LLC, and HAP Trading LLC.

Which institutional investors are buying Entera Bio stock?

ENTX stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and Morgan Stanley.

How do I buy shares of Entera Bio?

Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $3.16.

How much money does Entera Bio make?

Entera Bio has a market capitalization of $74.89 million and generates $370 thousand in revenue each year. The company earns $-9.98 million in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Entera Bio have?

Entera Bio employs 17 workers across the globe.

What is Entera Bio's official website?

The official website for Entera Bio is www.enterabio.com.

Where are Entera Bio's headquarters?

How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The company can be reached via phone at (722) 532-7151 or via email at [email protected].


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.